A newly developed technology for simultaneously comparing response to
multiple cancer drugs or combinations while a tumor is still in a
patient's body has been shown to accurately predict systemic response to
the drugs, according to researchers at Fred Hutchinson Cancer Research
Center and Presage Biosciences. The patented technology, called CIVO,
consists of an arrayed micro-injection drug delivery device and
quantitative analysis methodology. "Currently, only 7 percent of new oncology drug candidates that
demonstrated anti-cancer activity in preclinical studies subsequently
demonstrate sufficient efficacy in clinical trials to warrant FDA
approvals," said Olson, Member of the Clinical Research Division at Fred
Hutch, a pediatric oncologist at Seattle Children's Hospital and
Founder of Presage. "As a practicing pediatric oncologist, I deal every
day with the limitations of current cancer therapies, and I've made it
my life's work to help find solutions to this challenge. We developed
CIVO because patients desperately need better approaches to identify
treatments that will provide benefit and improve patient survival."
CIVO enables the placement of multiple columns of drugs for analysis directly into the tumor
along the needle axis, spanning the full depth of the tumor. This makes
it possible to assess drug effects with multiple biomarkers and in
multiple regions along the injection axis to capture the heterogeneity
of response within the tumor. Later, (typically 24-72 hours after
injection), the tumor is resected for subsequent analysis, and responses
are measured with multiple immuno-histochemistry-based assays and
high-resolution scanning.
No comments:
Post a Comment